Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Neuroprotective effects of resident microglia following acute brain injury.
European School of Neuroimmunology 15th Course
Episode 16 with Dr. Revere [double-quote]Rip[double-quote] Kinkel on how to improve patient outreach
Other National MS Societies (Not listed here)
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis.
Effirma, Synthetic Biologics
Novel MS Drugs Advance
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Keystone Symposium: Innate Immunity and Determinants of Microbial Pathogenesis - joint with - Mechanisms of Pro-Inflammatory Diseases
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.
Episode 9 with Dr. Amit Bar-Or on how pediatric MS can illuminate early mechanisms of the disease
Contribution of different relapse phenotypes to disability in multiple sclerosis.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Multiple sclerosis prevalence in the United States commercially insured population.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
8th World Congress on Controversies in Neurology (CONy)

Pages